I
Inthera Bioscience
Develops small molecular therapies for solid tumours
About Inthera Bioscience
Inthera Bioscience is an emerging Swiss biotechnology company focused on developing innovative and highly effective therapies for currently incurable cancers. The company specializes in designing small molecule inhibitors that target intracellular protein-protein interactions, a novel approach in cancer treatment. Their most advanced therapeutic candidate, a modulator of dysregulated transcription, is progressing towards clinical trials. Inthera Bioscience serves the oncology market, primarily targeting patients with cancers that have limited or no treatment options. The company operates on a research and development business model, generating revenue through partnerships, grants, and potential future sales of their therapeutic products.
Source: Dealroom company dataAt a glance
- Founded
- 2013
- Headquarters
- Zurich, Switzerland
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Aglaia BioMedical Ventures
Microsoft for Startups
EVA Basel
Series A3 investors entered at this stage
Novo Ventures
M Ventures
Novo Seeds
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inthera Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inthera Bioscience on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.